Sanaria, PATH Open Facility For Producing Novel Malaria Vaccine
Sanaria Inc., (Rockville, MD) and the PATH Malaria Vaccine Initiative have officially opened a clinical manufacturing facility to produce a vaccine that uses a weakened form of the malaria parasite to fight malaria, a disease that annually kills more than one million people.
Sanaria Inc., (Rockville, MD) and the PATH Malaria Vaccine Initiative have officially opened a clinical manufacturing facility to produce a vaccine that uses a weakened form of the malaria parasite to fight malaria, a disease that annually kills more than one million people. The event marks a major milestone in the effort to translate Sanaria’s approach into an effective weapon against the malaria parasite, Plasmodium falciparum.
Most malaria vaccines currently under development are subunit vaccines that consist of recombinant or genetically engineered proteins that represent a portion of the parasite believed to be capable of eliciting an immune response against the disease. Sanaria, however, is producing a live, attenuated vaccine that contains a weakened form of the entire organism.
The manufacturing facility was constructed to allow scientists to safely rear aseptically produced mosquitoes, feed them blood containing the malaria parasite, irradiate the insects to weaken the parasites, and harvest the parasites from the mosquito’s salivary glands. Sanaria seeks to use these parasites as the main component of a “whole-parasite” vaccine to be tested in a clinical trial in US adult volunteers next year.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
